Placeholder Banner

Patients, Scientists and Researchers Will Be Watching the State of the Union

February 4, 2020
Media Contact
Author-Profile-Andrew-Segerman

Ahead of tonight’s State of the Union Address, Jim Greenwood, President and CEO of the Biotechnology Innovation Organization, shared what he hopes President Trump will say to America’s patients counting on the development of new medicines and cures, and the scientists and researchers working in labs across the country to produce them. 

 

“What I hope [the President] doesn’t do is demonize the industry. BIO represents about 1,000 companies, most of them are small little outfits with a handful of scientists trying to cure diseases that have brutalized humans forever and we’re making tremendous progress. As long as we can follow the right moral precepts, I think we can get the job done and make patients have access to the medicines they need. ...

“No patient should ever do without the medicine that he or she needs because they cannot afford what’s required to come from their pockets.

“No policy should ever be acceptable to Congress, the President, a Governor or state legislator if it tends to drive investment away from biotech innovation, because there is a tremendous amount of hope resting there for patients if we can just keep the science going."

To learn more about the flaws of importing foreign price controls, visit bio.org/save-cures

###

 

Discover More
The Biotechnology Innovation Organization (BIO) this week hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating Covid-19. The two-day virtual…
Companies are Coming Together to Achieve Shared Goal of Eradicating the Virus  Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) underscored the industry’s commitment…
The Securities and Exchange Commission (SEC) has adopted regulatory changes to provide small public companies with a temporary exemption from Sarbanes-Oxley 404(b) compliance. 404(b) requires public companies to report on the internal controls they…